Biosign Appoints Former US Senator Alfonse D'Amato

TORONTO, July 22 /PRNewswire-FirstCall/ - Biosign Technologies Inc. (CNSX: BIO) ("Biosign", the "Company") announces the appointment of Former Senator Alfonse D'Amato to the Board of Directors of the Company.

Senator D'Amato commented, "I am thrilled to be joining the Biosign team. People need innovation; we're not getting any younger. It is truly exciting to be collaborating with a company that is dedicated to providing people the tools they need to better manage their health. I look forward to working with Biosign to address the cost, access, and innovation deficits that exist in the healthcare system."

Former Senator Alfonse D'Amato had a distinguished 18-year career in the U.S. Senate, served as chairman of the Senate Banking Committee, was a member of the Senate Appropriations Committee - specializing in defense and transportation issues - and served on the Senate Finance Committee. The former Senator is considered an expert in the legislative and political process. As such, Senator D'Amato keeps close relationships with Members of Congress, on both sides of the aisle, and is regularly called upon for his advice and counsel.

"We are very pleased that Mr. D'Amato has joined the Board of Directors of the company," stated Radu Leca, CEO of Biosign adding "we believe Mr. D'Amato's many years of experience will greatly benefit our Board, the company and our shareholders."

Senator D'Amato has served on several public company boards of directors. From 1999 to 2009 he was a member of the board of Computer Associates, where he served on both the audit and the compensation committees, and he is a former director of Cendant Corporation. He is a current board member for Signature Bank (NASDAQ:SBNY), and he is Chairman of the Board for the Poker Players Alliance, an industry group that supports a repeal of the restrictive US internet gambling laws.

About Biosign Technologies Inc.

Biosign provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information please visit www.biosign.com

The CNSX has neither approved nor disapproved the contents of this press release.

SOURCE Biosign Technologies Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED